BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 339 filers reported holding BIO-TECHNE CORP in Q2 2018. The put-call ratio across all filers is 3.84 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $573 | +1.8% | 8,000 | 0.0% | 0.02% | 0.0% |
Q1 2024 | $563 | -11.1% | 8,000 | -2.4% | 0.02% | -16.7% |
Q4 2023 | $633 | +13.4% | 8,200 | 0.0% | 0.02% | 0.0% |
Q3 2023 | $558 | -10.0% | 8,200 | +7.9% | 0.02% | -11.1% |
Q2 2023 | $620 | +14.4% | 7,600 | +4.1% | 0.03% | 0.0% |
Q1 2023 | $542 | -12.9% | 7,300 | -2.7% | 0.03% | -18.2% |
Q4 2022 | $622 | -99.9% | 7,500 | +275.0% | 0.03% | +6.5% |
Q3 2022 | $568,000 | -25.6% | 2,000 | -9.1% | 0.03% | -16.2% |
Q2 2022 | $763,000 | -23.4% | 2,200 | -4.3% | 0.04% | 0.0% |
Q1 2022 | $996,000 | -19.8% | 2,300 | -4.2% | 0.04% | -11.9% |
Q4 2021 | $1,242,000 | +2.6% | 2,400 | -4.0% | 0.04% | 0.0% |
Q3 2021 | $1,211,000 | -66.7% | 2,500 | -69.0% | 0.04% | -66.4% |
Q2 2021 | $3,635,000 | +40.5% | 8,073 | +19.2% | 0.12% | +21.4% |
Q1 2021 | $2,587,000 | +20.3% | 6,773 | 0.0% | 0.10% | +13.2% |
Q4 2020 | $2,151,000 | +10.3% | 6,773 | -14.0% | 0.09% | -1.1% |
Q3 2020 | $1,950,000 | -18.6% | 7,873 | -13.2% | 0.09% | -19.3% |
Q2 2020 | $2,396,000 | +39.3% | 9,073 | 0.0% | 0.11% | +9.6% |
Q1 2020 | $1,720,000 | +19.2% | 9,073 | +38.0% | 0.10% | +73.3% |
Q4 2019 | $1,443,000 | +12.2% | 6,573 | 0.0% | 0.06% | +3.4% |
Q3 2019 | $1,286,000 | -6.1% | 6,573 | 0.0% | 0.06% | -1.7% |
Q2 2019 | $1,370,000 | -10.0% | 6,573 | -14.3% | 0.06% | -9.2% |
Q1 2019 | $1,523,000 | +37.2% | 7,673 | 0.0% | 0.06% | +22.6% |
Q4 2018 | $1,110,000 | -38.0% | 7,673 | -12.5% | 0.05% | -22.1% |
Q3 2018 | $1,791,000 | +38.0% | 8,773 | 0.0% | 0.07% | +33.3% |
Q2 2018 | $1,298,000 | -17.2% | 8,773 | -15.4% | 0.05% | -15.0% |
Q1 2018 | $1,567,000 | +30.5% | 10,373 | +11.9% | 0.06% | +33.3% |
Q4 2017 | $1,201,000 | – | 9,273 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |